Withaphysalin A 

Withaphysalin A is a withanolide compound with anti-inflammatory and antioxidant activities. Withaphysalin A inhibits LPS (HY-D1056)-induced nuclear translocation of NF-κB p65, as well as phosphorylation of STAT3, ERK, JNK and p38 MAPK. Withaphysalin A upregulates the expression of HO-1. Withaphysalin A inhibits LPS-induced production of NO, PGE₂, IL-1β, IL-6 and TNF-α. Withaphysalin A downregulates LPS-induced expression of iNOS and COX-2. Withaphysalin A interacts with B-cell activating factor protein (BAFF) to exert inhibitory effects. Withaphysalin A exhibits ELOVL6 inhibitory activity. Withaphysalin A can be used in the research of inflammatory diseases, nephrotic syndrome and chronic myeloid leukemia^[1][2][3].

Withaphysalin A (0-50 μM; 1 h) potently inhibits LPS-induced NO production in RAW264.7 cells, with an IC₅₀ of 20.12 μM, and suppresses LPS-induced PGE₂ production^[1].
Withaphysalin A (0-50 μM; 1 h) dose-dependently inhibits LPS-induced production of IL-6, TNF-α, and IL-1β in RAW264.7 cells, with both protein and mRNA levels suppressed^[1].
Withaphysalin A (0-50 μM; 1) dose-dependently inhibits LPS-induced expression of iNOS and COX-2 (at both protein and mRNA levels) in RAW264.7 cells^[1].
Withaphysalin A (0-50 μM; 1 h) inhibits LPS-induced phosphorylation of ERK, JNK, p38 MAPK, and STAT3, and induces HO-1 protein expression in LPS-stimulated RAW264.7 cells^[1].
Withaphysalin A (50 μM; 1 h) inhibits LPS-induced nuclear translocation of NF-κB p65 in RAW264.7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

466.57

C₂₈H₃₄O₆

57423-72-0

Solid

White to off-white

CC(CC([C@@]1(OC([C@]23CCC4C([C@@]2(CCC31)O)CC=C5CC=CC([C@]45C)=O)=O)C)O6)=C(C)C6=O

Room temperature in continental US; may vary elsewhere.

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

• [1]. Li RJ, et al. The Anti-inflammatory Activities of Two Major Withanolides from Physalis minima Via Acting on NF-κB, STAT3, and HO-1 in LPS-Stimulated RAW264.7 Cells. Inflammation. 2017;40(2):401-413.  [Content Brief]

  [2]. Kardani AK, et al. Inhibition of B-cell activating factor activity using active compounds from Physalis angulata in the mechanism of nephrotic syndrome improvement: A computational approach. Narra J. 2024 Dec;4(3):e859.  [Content Brief]

  [3]. Tasneem A, et al. Exploring phytochemical inhibitors of fatty acid elongase ELOVL6 for targeted treatment of chronic myeloid leukemia: A comprehensive network-based drug discovery approach. Comput Biol Med. 2026;201:111342.  [Content Brief]